PLoS ONE · 2008 · 152 citations · 39 references
Life SciencesGeneticsNeuroscienceGene ExpressionNeurodegenerationNeurogeneticsGene SilencingGenetic DisordersNeurological Gene TherapyRna EditingRna InterferenceTranscriptional SilencingAllele-specific Ribonucleic Acid InterferenceAllele-specific Rna EditingAllele-specific SilencingGene Silencing In NeurodegenerationNeuropathological LesionsSingle-nucleotide Polymorphism AnalysisSingle-nucleotide Polymorphism VariationTherapeutic Gene Silencing
Recent studies have demonstrated that RNAi is a promising approach for treating autosomal dominant disorders. However, discrimination between wild-type and mutant transcripts is essential, to preserve wild-type expression and function. A single nucleotide polymorphism (SNP) is present in more than 70% of patients with Machado-Joseph disease (MJD). We investigated whether this SNP could be used to inactivate mutant ataxin-3 selectively. Lentiviral-mediated silencing of mutant human ataxin-3 was demonstrated in vitro and in a rat model of MJD in vivo. The allele-specific silencing of ataxin-3 significantly decreased the severity of the neuropathological abnormalities associated with MJD. These data demonstrate that RNAi has potential for use in MJD treatment and constitute the first proof-of-principle for allele-specific silencing in the central nervous system.
39
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
PubMed · 1997 · 66.6K citations
Rational siRNA design for RNA interference
Angela Reynolds, Devin Leake, Queta Boese et al. · Nature Biotechnology · 2004 · 2.1K citations
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1
Yoshiya Kawaguchi, Toshihiro Okamoto, Masafumi Taniwaki et al. · Nature Genetics · 1994 · 1.8K citations